Physician profile
Christopher Southwood
NPI 1215270616
$6,195.95
in general payments reported to CMS, 2019-2025
28 companies · $631 in 2025
The $631 reported for 2025 was more than what 85% of Neurocritical Care providers received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $154 · 2021: $641 · 2022: $540 · 2023: $1,303 · 2024: $1,602 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,536.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,339.18 | 2019-2024 | Red 72 |
| Stryker Corporation | $1,314.67 | 2021-2025 | Surpass Evolve, Target, Trevo |
| Depuy Synthes Sales INC. | $630.16 | 2019-2025 | Cerepak Uniform, Embotrap, Emboguard |
| Imperative Care, INC | $541.30 | 2021-2024 | Zoom 88-T Large Distal Platform, Zoom Reperfusion Catheter |
| Scientia Vascular | $164.41 | 2023 | |
| Microvention, INC. | $130.10 | 2023-2024 | Web Aneurysm Embolization System, Eric Retrieval Device, Sofia 6f-131cm Str |
| Lundbeck LLC | $116.39 | 2023-2024 | Vyepti |
| Philips North America LLC | $112.50 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $111.42 | 2023-2025 | Nuedexta, Rexulti |
| Astrazeneca Pharmaceuticals Lp | $94.23 | 2023-2024 | Andexxa |
| Medtronic, INC. | $79.94 | 2021-2025 | Pipeline |
| Catalyst Pharmaceuticals, INC. | $76.27 | 2023-2025 | Firdapse |
| Abbvie INC. | $72.99 | 2023-2024 | Duopa |
| Csl Behring | $51.59 | 2024 | Kcentra |
| Chiesi USA, INC. | $48.73 | 2023-2024 | Cleviprex |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $42.53 | 2023-2024 | |
| Siemens Medical Solutions USA, INC. | $35.01 | 2021 | |
| Amgen INC. | $34.43 | 2025 | |
| Route 92 Medical, INC. | $30.03 | 2025 | |
| Argenx US, INC. | $27.00 | 2025 | Vyvgart Hytrulo |
| Becton, Dickinson and Company | $26.73 | 2025 | Hemosphere |
| Life Molecular Imaging Ltd | $21.96 | 2024 | Neuraceq |
| Trisalus Life Sciences, INC. | $17.06 | 2024 | Trinav Infusion System |
| Lilly USA, LLC | $16.68 | 2023 | Amyvid |
| Abbott Laboratories | $16.30 | 2023 | Perclose Prostyle |
| Eisai INC. | $16.17 | 2024 | |
| Inspiremd Ltd | $15.18 | 2025 | Cguard Prime Carotid Stent System |
| Terumo Medical Corporation | $12.99 | 2023 | Glidewire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Southwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.